Publication Cover
Acta Clinica Belgica
International Journal of Clinical and Laboratory Medicine
Volume 77, 2022 - Issue 3
282
Views
1
CrossRef citations to date
0
Altmetric
Article

Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI)

, , ORCID Icon, , , & ORCID Icon show all
 

ABSTRACT

Vaccination against COVID-19 constitutes a huge hope and a major challenge. For the first time in modern history, a global vaccination campaign has started worldwide in a short period of time and with products that were recently developed. Consequently, legitimate concerns regarding the safety and tolerability of COVID-19 vaccines arise.

In line with international allergy societies, the Belgian Society for Allergy and Clinical Immunology (BelSACI) provides this statement to guide health care providers (general practitioners, specialists including allergists) and stakeholders.

In this statement, we first review current evidence on allergic reactions to vaccines and the potential risk factors that have been identified.

Second, we provide a risk stratification method that may be used as a worksheet during the vaccination campaign.

Finally, we discuss the management of suspected or confirmed allergic reactions following vaccination.

Disclosure statement

The authors declare that they have no conflict of interest to disclose in relation to this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.